Furthermore, the REWIND trial demonstrated a 12% reduction in major adverse cardiovascular events (MACE) ( p = 0.026), including among patients without established cardiovascular disease, alongside renoprotective effects evidenced by reductions in albuminuria [56]
Pataer A, He Y, Correa AM, Fang B, Roth JA, Wistuba II, Swisher SG
These results in agreement with the previous studies
Elafibranor and liraglutide improve differentially liver health and metabolism in a mouse model of non-alcoholic steatohepatitis
This isnt just a shift in SEO its a shift in patient expectations
One idea is to enhance the activity of amino acid metabolism of CAR-T cells by adding cytokines that promote the expression of transporters related to amino acid metabolism, such as SLC1A5, SLC3A2 and SLC7A5, or directly importing transcripts encoding these AATs into T cells